Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfectionYixian Zhang(Enzon Pharmaceuticals (United States)), Ivan D. Horak(Enzon Pharmaceuticals (United States))Gene TherapyDecember 23, 201010.1038/gt.2010.133Cited by 67SaveCiteExport RISWatch citationsRelated PapersCombination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus|Endocrine Related Cancer|2006|38